HS-10241-301
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
- NCT06110663 ↗
- Unknown
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Focused
We haven't built an HCP commentary report on HS-10241-301 (HS-10241+ almonertinib and pemetrexed + cisplatin /Carboplatin in Non-Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HS-10241-301 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-label, Multicenter Study to Assess the Efficacy and Safety of HS-10241 Combined With Almonertinib Versus Pemetrexed Combined With Platinum in Metastatic or Locally Advanced NSCLC With MET Amplification After Failure of the Prior EGFR -TKI Therapy
- Phase
- Phase 3
- Status
- Unknown
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- HS-10241+ Almonertinib; Pemetrexed + Cisplatin /Carboplatin
- Arms
- HS-10241+Almonertinib · Experimental
- Pemetrexed + Cisplatin /Carboplatin · Active comparator
- Enrollment
- 314 (estimated)
- Primary outcomes
- Progression-free Survival (PFS) evaluated by Independent Review Committee (IRC)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Start
- Dec 30, 2023 (estimated)
- Primary completion
- Dec 30, 2024 (estimated)
- Results posted
- No
- Registry record
- NCT06110663 · updated Nov 1, 2023